Oxford BioMedica to test TroVax in breast cancer patients

By Elaine Rigoli

Tampa, Fla., Sept. 5 - Oxford BioMedica plc said the Southwest Oncology Group, a U.S. clinical trials cooperative group, has received regulatory clearance to begin a phase 2 trial of Oxford BioMedica's cancer immunotherapy, TroVax, in patients with late-stage breast cancer.

The U.S. National Cancer Institute is sponsoring the trial and is responsible for the principal costs.

Approximately 120 patients will be enrolled in the open-label trial. Patients will receive monthly injections of TroVax for three months, followed by booster immunizations at six, nine and 12 months.

The Oxford, England-based gene-therapy company said key endpoints will include immunological response rates to the 5T4 tumor antigen and progression-free survival versus historical controls.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.